Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Evaluation of minor groove binders (MGBs) as novel anti-mycobacterial agents and the effect of using non-ionic surfactant vesicles as a delivery system to improve their efficacy.

Hlaka L, Rosslee MJ, Ozturk M, Kumar S, Parihar SP, Brombacher F, Khalaf AI, Carter KC, Scott FJ, Suckling CJ, Guler R.

J Antimicrob Chemother. 2017 Dec 1;72(12):3334-3341. doi: 10.1093/jac/dkx326.

2.

What happened at Vienna's Allgemeines Krankenhaus after Semmelweis's contract as Assistant in the First Maternity Division was terminated?

Jadraque PP, Carter KC.

Epidemiol Infect. 2017 Jul;145(10):2144-2151. doi: 10.1017/S0950268817000875. Epub 2017 May 2.

PMID:
28462740
3.

Is Hybridization a Source of Adaptive Venom Variation in Rattlesnakes? A Test, Using a Crotalus scutulatus × viridis Hybrid Zone in Southwestern New Mexico.

Zancolli G, Baker TG, Barlow A, Bradley RK, Calvete JJ, Carter KC, de Jager K, Owens JB, Price JF, Sanz L, Scholes-Higham A, Shier L, Wood L, Wüster CE, Wüster W.

Toxins (Basel). 2016 Jun 16;8(6). pii: E188. doi: 10.3390/toxins8060188.

4.

Chemical and Antimicrobial Profiling of Propolis from Different Regions within Libya.

Siheri W, Zhang T, Ebiloma GU, Biddau M, Woods N, Hussain MY, Clements CJ, Fearnley J, Ebel RE, Paget T, Muller S, Carter KC, Ferro VA, De Koning HP, Watson DG.

PLoS One. 2016 May 19;11(5):e0155355. doi: 10.1371/journal.pone.0155355. eCollection 2016.

5.

Nanocarriers Made from Non-Ionic Surfactants or Natural Polymers for Pulmonary Drug Delivery.

Carter KC, Puig-Sellart M.

Curr Pharm Des. 2016;22(22):3324-31. Review.

PMID:
27087597
6.

In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization.

Shaw CD, Lonchamp J, Downing T, Imamura H, Freeman TM, Cotton JA, Sanders M, Blackburn G, Dujardin JC, Rijal S, Khanal B, Illingworth CJ, Coombs GH, Carter KC.

Mol Microbiol. 2016 Mar;99(6):1134-48. doi: 10.1111/mmi.13291. Epub 2016 Feb 9.

7.

Drug delivery: lessons to be learnt from Leishmania studies.

Shaw CD, Carter KC.

Nanomedicine (Lond). 2014 Jul;9(10):1531-44. doi: 10.2217/nnm.14.66. Review.

8.

The isolation of antiprotozoal compounds from Libyan propolis.

Siheri W, Igoli JO, Gray AI, Nasciemento TG, Zhang T, Fearnley J, Clements CJ, Carter KC, Carruthers J, Edrada-Ebel R, Watson DG.

Phytother Res. 2014 Dec;28(12):1756-60. doi: 10.1002/ptr.5194. Epub 2014 Jul 9.

9.
10.

Infectivity of macrophages and the histopathology of cutaneous lesions, liver and spleen is attenuated by leaf extract of Vernonia amygdalina in Leishmania major infected BALB/c mice.

Alawa JN, Carter KC, Nok AJ, Kwanashie HO, Adebisi SS, Alawa CB, Clements CJ.

J Complement Integr Med. 2012 Jun 18;9:Article 10. doi: 10.1515/1553-3840.1617.

PMID:
22713278
11.

The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection.

Alsaadi M, Italia JL, Mullen AB, Ravi Kumar MN, Candlish AA, Williams RA, Shaw CD, Al Gawhari F, Coombs GH, Wiese M, Thomson AH, Puig-Sellart M, Wallace J, Sharp A, Wheeler L, Warn P, Carter KC.

J Control Release. 2012 Jun 28;160(3):685-91. doi: 10.1016/j.jconrel.2012.04.004. Epub 2012 Apr 10.

PMID:
22516093
12.

Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.

Campbell SA, Alawa J, Doro B, Henriquez FL, Roberts CW, Nok A, Alawa CB, Alsaadi M, Mullen AB, Carter KC.

Vaccine. 2012 Feb 8;30(7):1357-63. doi: 10.1016/j.vaccine.2011.12.067. Epub 2011 Dec 28.

PMID:
22210224
13.

Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™.

Italia JL, Sharp A, Carter KC, Warn P, Kumar MN.

PLoS One. 2011;6(10):e25744. doi: 10.1371/journal.pone.0025744. Epub 2011 Oct 6.

14.

Endogenous IL-13 plays a crucial role in liver granuloma maturation during Leishmania donovani infection, independent of IL-4Rα-responsive macrophages and neutrophils.

McFarlane E, Carter KC, McKenzie AN, Kaye PM, Brombacher F, Alexander J.

J Infect Dis. 2011 Jul 1;204(1):36-43. doi: 10.1093/infdis/jir080.

15.

Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection.

Henriquez FL, Campbell SA, Roberts CW, Mullen AB, Burchmore R, Carter KC.

J Parasitol. 2010 Oct;96(5):929-36. doi: 10.1645/GE-2360.1. Epub 2010 Apr 17.

PMID:
20950100
16.

Change of type as an explanation for the decline of therapeutic bloodletting.

Carter KC.

Stud Hist Philos Biol Biomed Sci. 2010 Mar;41(1):1-11. doi: 10.1016/j.shpsc.2009.12.007. Epub 2010 Feb 1.

PMID:
20185079
17.

Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection.

Mann JF, Shakir E, Carter KC, Mullen AB, Alexander J, Ferro VA.

Vaccine. 2009 Jun 2;27(27):3643-9. doi: 10.1016/j.vaccine.2009.03.040. Epub 2009 Apr 5.

PMID:
19464545
18.

Toll-like receptor-4-mediated macrophage activation is differentially regulated by progesterone via the glucocorticoid and progesterone receptors.

Jones LA, Anthony JP, Henriquez FL, Lyons RE, Nickdel MB, Carter KC, Alexander J, Roberts CW.

Immunology. 2008 Sep;125(1):59-69. doi: 10.1111/j.1365-2567.2008.02820.x. Epub 2008 Mar 28.

19.

Neutrophils contribute to development of a protective immune response during onset of infection with Leishmania donovani.

McFarlane E, Perez C, Charmoy M, Allenbach C, Carter KC, Alexander J, Tacchini-Cottier F.

Infect Immun. 2008 Feb;76(2):532-41. Epub 2007 Dec 3.

20.

Differential cytotoxicity of phospholipid analogues to pathogenic Acanthamoeba species and mammalian cells.

McBride J, Mullen AB, Carter KC, Roberts CW.

J Antimicrob Chemother. 2007 Sep;60(3):521-5. Epub 2007 Jul 10.

PMID:
17623692
21.

DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection.

Carter KC, Henriquez FL, Campbell SA, Roberts CW, Nok A, Mullen AB, McFarlane E.

Vaccine. 2007 May 30;25(22):4502-9. Epub 2007 Mar 26.

PMID:
17418459
22.

Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude.

Qu X, Khutoryanskiy VV, Stewart A, Rahman S, Papahadjopoulos-Sternberg B, Dufes C, McCarthy D, Wilson CG, Lyons R, Carter KC, Schätzlein A, Uchegbu IF.

Biomacromolecules. 2006 Dec;7(12):3452-9.

PMID:
17154474
23.

Identification of the benzodiazepines as a new class of antileishmanial agent.

Clark RL, Carter KC, Mullen AB, Coxon GD, Owusu-Dapaah G, McFarlane E, Duong Thi MD, Grant MH, Tettey JN, Mackay SP.

Bioorg Med Chem Lett. 2007 Feb 1;17(3):624-7. Epub 2006 Nov 6.

PMID:
17113290
24.

Protozoan parasites: familiar faces, new directions.

Carter KC, Phillips RS, Roberts CW.

Parasitol Today. 1998 Sep;14(9):341-2. No abstract available.

PMID:
17040810
25.
26.

Mucosal immunisation: Successful approaches to targeting different tissues.

Ferro VA, Carter KC.

Methods. 2006 Feb;38(2):61-4. No abstract available.

PMID:
16442812
27.

Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity.

Mann JF, Scales HE, Shakir E, Alexander J, Carter KC, Mullen AB, Ferro VA.

Methods. 2006 Feb;38(2):90-5.

PMID:
16414269
28.

Translation of an experimental oral vaccine formulation into a commercial product.

Carter KC, Ferro VA, Alexander J, Mullen AB.

Methods. 2006 Feb;38(2):65-8. Review.

PMID:
16406571
29.

Resistance of Leishmania donovani to sodium stibogluconate is related to the expression of host and parasite gamma-glutamylcysteine synthetase.

Carter KC, Hutchison S, Henriquez FL, Légaré D, Ouellette M, Roberts CW, Mullen AB.

Antimicrob Agents Chemother. 2006 Jan;50(1):88-95.

30.

Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy.

Carter KC, Hutchison S, Boitelle A, Murray HW, Sundar S, Mullen AB.

Parasitology. 2005 Dec;131(Pt 6):747-57.

PMID:
16336728
31.

Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin.

Mann JF, Ferro VA, Mullen AB, Tetley L, Mullen M, Carter KC, Alexander J, Stimson WH.

Vaccine. 2004 Jun 23;22(19):2425-9.

PMID:
15193405
32.

Immune responses to a GnRH-based anti-fertility immunogen, induced by different adjuvants and subsequent effect on vaccine efficacy.

Ferro VA, Costa R, Carter KC, Harvey MJ, Waterston MM, Mullen AB, Matschke C, Mann JF, Colston A, Stimson WH.

Vaccine. 2004 Feb 25;22(8):1024-31.

PMID:
15161080
33.

Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals.

Nieto J, Alvar J, Mullen AB, Carter KC, Rodríguez C, San Andrés MI, San Andrés MD, Baillie AJ, González F.

Antimicrob Agents Chemother. 2003 Sep;47(9):2781-7.

34.
35.

The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis.

Carter KC, Sundar S, Spickett C, Pereira OC, Mullen AB.

Antimicrob Agents Chemother. 2003 May;47(5):1529-35.

36.

Early conjectures that Down syndrome is caused by chromosomal nondisjunction.

Carter KC.

Bull Hist Med. 2002 Fall;76(3):528-63.

PMID:
12486916
37.

An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection.

Alexander J, Brombacher F, McGachy HA, McKenzie AN, Walker W, Carter KC.

Eur J Immunol. 2002 Oct;32(10):2923-33.

38.

The effect of nitrostyrene on cell proliferation and macrophage immune responses.

Carter KC, Finnon YS, Daeid NN, Robson DC, Waddell R.

Immunopharmacol Immunotoxicol. 2002 May;24(2):187-97.

PMID:
12066846
39.

Edwin Klebs's Grundversuche.

Carter KC.

Bull Hist Med. 2001 Winter;75(4):771-81.

PMID:
11740130
40.

Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani.

Carter KC, Mullen AB, Sundar S, Kenney RT.

Antimicrob Agents Chemother. 2001 Dec;45(12):3555-9.

41.

Leechcraft in nineteenth century British medicine.

Carter KC.

J R Soc Med. 2001 Jan;94(1):38-42. No abstract available.

42.

Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis.

Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F.

Eur J Immunol. 2000 Oct;30(10):2935-43.

43.
44.

Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer.

Xu LL, Srikantan V, Sesterhenn IA, Augustus M, Dean R, Moul JW, Carter KC, Srivastava S.

J Urol. 2000 Mar;163(3):972-9.

PMID:
10688034
45.

Siglec-8. A novel eosinophil-specific member of the immunoglobulin superfamily.

Floyd H, Ni J, Cornish AL, Zeng Z, Liu D, Carter KC, Steel J, Crocker PR.

J Biol Chem. 2000 Jan 14;275(2):861-6.

46.

Cloning and functional analysis of the human IRF-3 promoter.

Lowther WJ, Moore PA, Carter KC, Pitha PM.

DNA Cell Biol. 1999 Sep;18(9):685-92.

PMID:
10492399
47.

Reed-Sternberg cell genome expression supports a B-cell lineage.

Cossman J, Annunziata CM, Barash S, Staudt L, Dillon P, He WW, Ricciardi-Castagnoli P, Rosen CA, Carter KC.

Blood. 1999 Jul 15;94(2):411-6.

48.
50.

VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo.

Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C, Carter KC, Janat F, Kozak D, Xu S, Rojas L, Aggarwal BB, Ruben S, Li LY, Gentz R, Yu GL.

FASEB J. 1999 Jan;13(1):181-9.

PMID:
9872942

Supplemental Content

Loading ...
Support Center